Conference Call with Ipca Laboratories Management and Analysts on Q1FY27 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ipca Laboratories announced Q1FY27 results Standalone Financial Highlights: Total Income for Q1FY27 stood at Rs 2,136.66 crore, representing a YoY increase of 20.58% compared to Rs 1,771.92 crore in Q1FY26 and a QoQ increase of 15.86% from Rs 1,844.23 crore in Q4FY26. Revenue from Operations reached Rs 2,119.24 crore in Q1FY27, up 21.31% YoY from Rs 1,746.90 crore in Q1FY26 and up 16.80% QoQ from Rs 1,814.35 crore in Q4FY26. Profit Before Tax (PBT) for Q1FY27 was Rs 515.41 crore, showing a YoY growth of 44.47% compared to Rs 356.75 crore in Q1FY26 and a QoQ growth of 47.32% from Rs 349.85 crore in Q4FY26. Net Profit after tax for the quarter was reported at Rs 373.29 crore in Q1FY27, growing by 42.46% YoY from Rs 262.04 crore in Q1FY26 and 42.32% QoQ from Rs 262.29 crore in Q4FY26. EBITDA margin (before forex gain/loss and other income) improved to 26.27% in Q1FY27 compared to 23.82% in Q1FY26. Other Income was Rs 17.42 crore in Q1FY27, a decrease of 30.38% YoY from Rs 25.02 crore in Q1FY26. Basic Earnings Per Share (EPS) stood at Rs 14.71 for Q1FY27, compared to Rs 10.33 in Q1FY26 and Rs 10.34 in Q4FY26. Consolidated Financial Highlights: Total Income for Q1FY27 was Rs 2,813.36 crore, reflecting a YoY growth of 20.15% from Rs 2,341.51 crore in Q1FY26 and a QoQ growth of 13.34% from Rs 2,482.22 crore in Q4FY26. Revenue from Operations grew by 20.76% YoY to Rs 2,788.10 crore in Q1FY27, compared to Rs 2,308.85 crore in Q1FY26. It also increased by 16.73% QoQ from Rs 2,388.48 crore in Q4FY26. Profit Before Tax (PBT) for the quarter stood at Rs 572.08 crore in Q1FY27, up 73.09% YoY from Rs 330.51 crore in Q1FY26 and up 41.45% QoQ from Rs 404.45 crore in Q4FY26. Net Profit attributable to owners of the parent was reported at Rs 401.89 crore in Q1FY27, a growth of 72.33% YoY compared to Rs 233.21 crore in Q1FY26 and a growth of 34.38% QoQ from Rs 299.07 crore in Q4FY26. EBITDA margin (before forex gain/loss and other income) for Q1FY27 was 22.88%, compared to 18.39% in Q1FY26. Other Income was Rs 25.26 crore in Q1FY27, representing a YoY decrease of 22.66% from Rs 32.66 crore in Q1FY26. Basic Earnings Per Share (EPS) for Q1FY27 stood at Rs 15.84, against Rs 9.19 in Q1FY26 and Rs 13.31 in Q4FY26. Business Highlights: Revenue Break-up by Products: Formulations: Total formulations revenue grew by 19% YoY to Rs 1,685.16 crore in Q1FY27. Domestic formulations contributed Rs 1,082.12 crore (up 13% YoY), while exports were Rs 603.04 crore (comprising Branded at Rs 143.27 crore, up 16% YoY; Institutional at Rs 119.75 crore, up 107% YoY; and Generics at Rs 340.02 crore, up 27% YoY). APIs: Total APIs revenue stood at Rs 423.72 crore in Q1FY27, marking a growth of 30% YoY. Domestic API sales were Rs 91.37 crore (up 20% YoY) and Export API sales were Rs 332.35 crore (up 33% YoY). Geographic Performance: Revenue from India was Rs 1,229.21 crore in Q1FY27, compared to Rs 1,083.17 crore in Q1FY26. Revenue from Outside India was Rs 1,558.89 crore in Q1FY27, compared to Rs 1,225.68 crore in Q1FY26. Other Developments: The Board of Directors, in their meeting held on June 26, 2026, resolved to amalgamate M/s. Krebs Biochemicals & Industries Ltd. with the company, with an appointed date of April 1, 2026. However, no effect for this amalgamation has been given in the unaudited financial results pending necessary consents/approvals. Result PDF